Skip to content
Screener

Arvinas ARVN Total Current Liabilities

Total Current Liabilities at other companies

Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
$72.02M-4.8%
LON
LeonaBio, Inc.LONA
$6.67M+21.4%
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
$71.33M-18.5%
Monte Rosa Therapeutics, Inc. logo
Monte Rosa Therapeutics, Inc.GLUE
$59.66M+42.5%
Relmada Therapeutics, Inc. logo
Relmada Therapeutics, Inc.RLMD
$12.89M+146%
ArriVent BioPharma, Inc. logo
ArriVent BioPharma, Inc.AVBP
$25M+93.0%

Other financials

Income statement

See full
Revenue$15.6M-91.7%
Operating income-$63.8M-189%
Net income-$57.6M-169%
EPS (diluted)-$0.90-179%

Balance sheet

See full
Cash & equivalents$87.3M+7.8%
Total debt$8.6M-19.6%
Total equity$386.8M-41.4%
Total assets$647.5M-35.3%

Cash flow

See full
Operating cash flow-$69.2M+22.2%
CapEx$1.3M+225%
Free cash flow-$70.5M+21.1%

Valuation

See full
Market cap$572.13M+18.3%
Enterprise value$493.43M+30.3%
P/S6.4×+5.1×

Profitability

See full
Operating margin-283.8%-310pp
Net margin-247.5%-260pp
FCF margin-287.4%

Returns & leverage

See full
Return on equity-42.3%-53.5pp
Debt / equity0.0×
Current ratio5.4×+0.9×

Where this comes from

Reported directly by Arvinas in its filing.

Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.

The source filing: Arvinas’s 10-Q, filed May 11, 2026.

Filed
May 11, 2026, 5:18 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001628280-26-033669
(dollars and shares in millions, except per share amounts)March 31,2026December 31,2025
Accounts payable and accrued liabilities$62.3$69.5
Deferred revenue51.871.3
Current portion of operating lease liabilities1.81.7
Total current liabilities115.9142.5
Deferred revenue138.2134.3
Long-term debt0.30.4
Operating lease liabilities6.36.8
Total liabilities260.7284.0

Item 1. Financial Statements (Unaudited)

FAQ

What is Arvinas's total current liabilities?
Arvinas (ARVN) reported total current liabilities of $115.9M in Q1 2026.
How has Arvinas's total current liabilities changed year-over-year?
Arvinas's total current liabilities decreased by 45.8% year-over-year, from $214M to $115.9M.
What is the long-term trend for Arvinas's total current liabilities?
Over 5 years (2020 to 2025), Arvinas's total current liabilities has grown at a 23.7% compound annual growth rate (CAGR), from $49.2M to $142.5M.
What does total current liabilities mean?
The sum of all obligations due within one year — payables, accrued expenses, current debt, deferred revenue, and other short-term liabilities.

Ask your AI about Arvinas's total current liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude